CTSS

Across TCGA pan-cancer cohorts, CTSS mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CTSS data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTSS mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CTSS expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, GBM, and HNSC are the cancer types where CTSS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.933	0.628	.006	18	view →
GBM	DFS	Tertile	All	0.652	0.853	.008	5	view →
HNSC	DFS	Median	All	0.921	0.980	.032	2	view →
LUAD	DFS	Tertile	II,III,IV	0.739	0.364	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CTSS–PDAC (DFS)

Open the PDAC breakdown →